Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) Equity Average (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Equity Average for 7 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average rose 44.56% to $1.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 billion, a 44.56% increase, with the full-year FY2025 number at $986.0 million, up 14.99% from a year prior.
  • Equity Average was $1.1 billion for Q4 2025 at Beam Therapeutics, up from $1.0 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.1 billion in Q4 2025 to a low of $334.0 million in Q1 2021.
  • A 5-year average of $811.6 million and a median of $818.7 million in 2022 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: skyrocketed 1007.96% in 2021, then dropped 13.84% in 2022.
  • Beam Therapeutics' Equity Average stood at $840.3 million in 2021, then fell by 13.84% to $724.0 million in 2022, then increased by 21.57% to $880.1 million in 2023, then dropped by 13.37% to $762.4 million in 2024, then soared by 44.56% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Equity Average are $1.1 billion (Q4 2025), $1.0 billion (Q3 2025), and $1.1 billion (Q2 2025).